Expand all sections

Rilonacept

Extended indication Treatment of idiopathic pericarditis
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Rilonacept
Domain Cardiovascular diseases
Reason of inclusion Biosimilar
Main indication Other medication for cardiovascular diseases
Extended indication Treatment of idiopathic pericarditis
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date October 2024
Expected Registration July 2025
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.